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Abstract Mutations in the bone morphogenetic protein
receptor (BMPR2) gene have been observed in 70 % of pa-
tients with heritable pulmonary arterial hypertension (HPAH)
and in 11–40 % with idiopathic PAH (IPAH). However, car-
riers of a BMPR2mutation have only 20 % risk of developing
PAH. Since inflammatory mediators are increased and predict
survival in PAH, they could act as a second hit inducing the
development of pulmonary hypertension in BMPR2 mutation
carriers. Our specific aim was to determine whether inflam-
matory mediators could contribute to pulmonary vascular cell
dysfunction in PAH patients with and without a BMPR2 mu-
tation. Pulmonary microvascular endothelial cells (PMEC)
and arterial smooth muscle cells (PASMC) were isolated from
lung parenchyma of transplanted PAH patients, carriers of a
BMPR2mutation or not, and from lobectomy patients or lung
donors. The effects of CRP and TNFα on mitogenic activity,
adhesiveness capacity, and expression of adhesion molecules
were investigated in PMECs and PASMCs. PMECs from
BMPR2 mutation carriers induced an increase in PASMC mi-
togenic activity; moreover, endothelin-1 secretion by PMECs
from carriers was higher than by PMECs from non-carriers.
Recruitment of monocytes by PMECs isolated from carriers
was higher compared to PMECs from non-carriers and from
controls, with an elevated ICAM-1 expression. CRP increased
adhesion of monocytes to PMECs in carriers and non-carriers,
and TNFα only in carriers. PMEC from BMPR2 mutation
carriers have enhanced adhesiveness for monocytes in re-
sponse to inflammatory mediators, suggesting that BMPR2
mutation could generate susceptibility to an inflammatory
insult in PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a severe progressive
disease defined hemodynamically by a mean pulmonary arte-
rial pressure (mPAP) higher than 25 mmHg, a pulmonary
vascular resistance (PVR) higher than 3 Woods units and a
pulmonary artery wedge pressure (PAWP) lower than
15 mmHg. PAH is characterized by a distal pre-capillary
arteriopathy, resulting in increased pulmonary vascular resis-
tance, right ventricular hypertrophy, progressive right heart
failure, and ultimately death [17, 30]. Idiopathic PAH
(IPAH) is sporadic when no familial history or identified risk
factor is reported [38]. In patients with a familial history of
PAH, germline mutations in the bone morphogenetic protein
receptor type 2 (BMPR2) gene are detected in 70% of patients
* Rozenn Quarck
rozenn.quarck@kuleuven.be
1 Respiratory Division, Department of Clinical and Experimental
Medicine, University of Leuven, Leuven, Belgium
2 UMR-S 999, INSERM and Université Paris–Sud, Laboratoire
d’Excellence (LabEx) en Recherche sur le Médicament et
l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie
Lannelongue, Le Plessis-Robinson, France
3 Respiratory Division, University Hospitals and Department of
Clinical and Experimental Medicine, University of Leuven,
Leuven, Belgium
4 Service de Chirurgie Thoracique, Vasculaire et de Transplantation
Cardio-Pulmonaire, Laboratoire de Recherche Chirurgicale,
INSERM U999, Centre Chirurgical Marie Lannelongue, Université
Paris–Sud, Le Plessis-Robinson, France
5 Experimental Thoracic Surgery and Thoracic Surgery Unit,
University Hospitals, University of Leuven, Leuven, Belgium
Pflugers Arch - Eur J Physiol
DOI 10.1007/s00424-016-1899-1
[42]. However, BMPR2 gene mutations have also been detect-
ed in up to 25 % of apparently idiopathic cases without any
familial history [42]. BMPR2 mutation carriers develop PAH
10 years earlier than non-carriers and have a more severe
hemodynamic compromise and a reduced response to vasodi-
lator testing [9, 28, 35]. Bone morphogenetic proteins, mem-
bers of the TGF-β superfamily, bind to BMPRII and are
involved in cellular functions including osteogenesis, cell dif-
ferentiation, growth, and homeostasis [22, 24]. Identification
of BMPR2 mutations in PAH patients has highlighted the
relevance of the TGF-β superfamily of receptors in the
pathophysiology of PAH. Accordingly, bone morphogenetic
protein and TGFβ1 signalling plays a major role in the path-
ogenesis of PAH as evidenced by (i) the involvement of down-
stream effectors of BMP receptor, SMAD proteins [45], and
(ii) the identification of mutations in other TGF-beta family
receptor members or related downstream signalling proteins,
including ALK1, endoglin, and SMAD9 in a small percentage
of heritable PAH cases [21, 42]. Among BMPR2 mutation
carriers, only 20 % will later develop PAH, which suggests
that a BMPR2 mutation alone is not sufficient to cause PAH
[42]. Interestingly, increased susceptibility to pulmonary hy-
pertension is observed heterozygous null BMPR2 mice when
an additional inflammatory stimulus is applied [39], under
hypoxia [1], or infusion of serotonin [19]. More recently,
Sawada et al. [37] have shown an increase in the translation
of the cytokine granulocyte macrophage colony-stimulating
factor (GM-CSF) in BMPR2 deficient human pulmonary
artery endothelial cells (PAEC) following tumour necrosis
factor alpha (TNFα) stimulation. In human PAH, the patho-
physiological processes commonly involved are vascular
remodelling, vasoconstriction, thrombosis, and inflammation
[15]. Vascular remodelling involves pulmonary arterial
smooth muscle cell (PASMC) and PAEC proliferation, migra-
tion, and mesenchymal transition [25, 34]. In addition,
perivascular inflammation may contribute to vascular remod-
elling [7, 25, 43]. Circulating levels of cytokines including
interleukin (IL)-1β, IL-6, and TNFα are increased, and cyto-
kine and chemokine-dependent mechanisms lead to inflam-
matory cell recruitment in human PAH [10, 13, 33, 36, 40].
It is currently and widely accepted that inflammation and au-
toimmunity can contribute to PAH pathobiology [4]. More
recently, BMPRII deficiency has been shown to increase cy-
tokine production [41]. We have shown that circulating levels
of C-reactive protein (CRP), a well-known inflammatory
marker, are increased in PAH and can predict adverse out-
comes in PAH patients [31]. The effects of CRP at the cellular
level have not been studied in PAH.
We determined whether loss of BMPRII signalling
could modify basal levels of inflammatory molecule ex-
pression and cellular response to circulating inflammatory
mediators in PMECs and PASMCs. Therefore, we investi-
gated the effects of the inflammatory mediators TNFα and
CRP on pulmonary vascular cell function in PAH patients
with impaired BMPRII signalling.
Materials and methods
Materials
Cell culture media including Dulbecco’s modified Eagle’s me-
dium (DMEM) and RPMI, foetal bovine serum (FBS), peni-
cillin, streptomycin, fungizone, dispase, Hank’s balanced salt
solution (HBSS), phosphate buffered saline (PBS), 4′,6-
diamidino-2-phenylindole (DAPI), TRIzol, SuperScript™ III
First-Strand Synthesis System, primers, RT2 SYBR Green/
ROX qPCR Master Mix, and secondary antibodies conjugat-
ed with Alexa Fluor were purchased from Life Technologies.
Vascular cell adhesion molecule-1 (VCAM-1) primers were
purchased from Integrated DNA Technologies. Pre-designed
endothelin converting enzyme-1 (ECE-1) primers were pur-
chased from Bio-Rad. Fibronectin, TNFα, and highly puri-
fied, endotoxin-free human recombinant CRP were purchased
from R&D Systems. Gelatin and bovine serum albumin
(BSA) were purchased from Sigma-Aldrich. [3H]-thymidine
(specific activity 74 GBq mmol−1) was from Perkin Elmer.
RNeasy Mini Kit and RNase-Free DNase set were purchased
from Qiagen. Anti-human CD31 antibody coupled to
allophycocyanin fluorochrome (CD31-APC) was from
Miltenyi Biotec. Lab-Tek chamber slides were from Nunc.
U937 cells were a gift from the laboratory of clinical immu-
nology (KU Leuven, Belgium). Monoclonal antibodies raised
in mouse against human alpha smooth muscle actin (α-SMA;
clone 1A4), human desmin, human CD31 (clone JC70A), and
human von Willebrand factor (vWF) (clone F8/86) were pur-
chased from Dako. Polyclonal antibody raised in rabbit
against human smooth muscle myosin heavy chain
(SMMHC) was from Biomedical Technologies. Acetylated
low-density lipoprotein (LDL) coupled to a fluorescent
carbocyanine dye, 1,1\′-dioctadecyl-3,3,3\′,3\′-tetramethyl-
indocarbocyanine perchlorate (DiI-Ac-LDL), was purchased
from Tebu-Bio. Monoclonal antibodies raised in mouse
against human intercellular adhesion molecule-1 (ICAM-1)
and VCAM-1 were from R&D Systems and polyclonal anti-
bodies raised in rabbit against peptide comprising amino-acids
950 to C-terminus of human BMPRII were from abcam.
Mouse monoclonal antibody against β-actin (clone AC-74)
was from Sigma. Secondary antibodies conjugated with
horseradish peroxidase were from Jackson.
PMECs were cultured in microvascular endothelial cell
growth medium containing 6 % growth supplement, 100 U/
mL penicillin, 100 μg/mL streptomycin, and 1.25 μg/mL
fungizone and starved in microvascular endothelial cell medi-
um supplemented with 0.2 % growth supplement.
Microvascular PASMC were cul tured in DMEM
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supplemented with 10 % FBS, 100 U/mL penicillin, 100 μg/
mL streptomycin, and 1.25 μg/mL fungizone and starved in
DMEM supplemented with 0.2 % FBS, 100 U/mL penicillin,
100 μg/mL streptomycin, and 1.25 μg/mL fungizone. U937
cells were cultured in RPMI containing 10 % FBS, 100 U/mL
penicillin, 100 μg/mL streptomycin, and 1.25 μg/mL
fungizone.
Tissue collection and cell isolation
Lung parenchyma was collected at the time of lung transplan-
tation from PAH patients without BMPR2 mutation (non-car-
riers; n = 7) and PAH patients with BMPR2mutation (carriers;
n = 5). In addition, lung parenchyma was collected from con-
trol subjects at the time of lobectomy or pneumonectomy for
suspected localized lung tumor (n = 3) and from an unused
donor lung (n = 1). The study protocol was approved by the
Institutional Ethics Committee of the University of Leuven
and participants gave written informed consent.
To isolate PMEC, a peripheral section of lung parenchyma
was cut into 5-mm pieces and enzymatically digested using
2 U/mL dispase in HBSS for 90min at 37 °C. The sample was
vortexed and flushed with a 10-mL pipette at 20-min intervals
during digestion. The tissue homogenate was filtered using a
70-μm cell strainer (BD Falcon) and the filtrate was centri-
fuged for 8 min, at 20 °C, at 500×g. The cell pellet was re-
suspended and microvascular PMEC were cultured in gelatin-
coated (2 mg/mL) 6-well plates in microvascular endothelial
cell growth medium containing 6 % growth supplement,
100 U/mL penicillin, 100 μg/mL streptomycin, and 1.25 μg/
mL fungizone. When the cells reached 90 % confluence,
immunomagnetic purification of PMEC was performed using
CD31 monoclonal antibody-labelled microbeads (Miltenyi
Biotec) as previously described [47]. Immunomagnetic puri-
fication of PMEC was repeated three times at 1-week
intervals.
Microvascular pulmonary arteries with a diameter smaller
than 500 μm were dissected in the laboratory under a micro-
scope from sections of lung parenchyma. To prevent any con-
tamination by fibroblasts, adventitial tissue was removed from
pulmonary arterial sections using forceps. PASMC were iso-
lated using the explant-outgrowth method previously de-
scribed [32] and cultured in DMEM supplemented with
10 % FBS. All experiments with PMEC and PASMC were
carried out with cells which have undergone less than 8
passages.
Phenotyping of PMEC and PASMC
Primary PMEC were phenotyped as previously described
[32]. Briefly, PMEC phenotype was characterized by labelling
cells with diI-Ac-LDL and by immunofluorescence using
monoclonal antibodies against human CD31 and human
vWF. In addition, CD31 positive, viable PMEC were quanti-
fied by fluorescent-activated cell sorting (FACS, FacsCanto II,
Bec ton Dick inson) . Ce l l s were incuba ted wi th
allophycocyanin (APC)-conjugated CD31 antibody
(Miltenyi Biotec) for 15 min at 4 °C. Stained cells were
washed and at least 10,000 events were measured by FACS.
Microvascular PASMCswere phenotyped by immunofluores-
cence using antibodies raised against α-SMA, desmin and
human SMMHC as previously described [32]. For quantifica-
tion of immunofluorescence staining, 10 images from non-
overlapping fields on each slide were captured at ×40 magni-
fication. Cells were counted by a single observer, unaware of
the identity of each section.
Cell proliferation
Subconfluent microvascular PASMCswere starved for 96 h in
DMEM supplemented with 0.2 % FBS, and PMEC were
starved for 24 h in microvascular endothelial cell medium
supplemented with 0.2 % growth supplement. Mitogenic ac-
tivity of PASMC was measured by adding increasing concen-
trations of FBS or 10 μg/mL CRP and 0.5 μCi/mL of [3H]-
thymidine (74 GBq/mmol, GE Healthcare) for 48 h. PMEC
proliferation was measured by adding increasing concentra-
tions of growth supplement and 0.5 μCi/mL of [3H]-thymi-
dine for 18 h. Trichloroacetic acid-insoluble cell material was
solubilized in 0.2 N NaOH and radioactivity incorporation
was quantified in a β-scintillation liquid counter as previously
described [32]. Experiments were performed in triplicate.
Data are expressed as fold increase vs. control (0.2 % FBS).
Co-culture of PMEC and PASMC
PMEC were seeded at a density of 45,000 cells/cm2 on
gelatin-coated Transwell® inserts (12 mm diameter, 0.4 μm
pore size, Corning). Confluent PMECwere starved for 24 h in
microvascular endothelial cell starving medium. In parallel,
subconfluent PASMC were starved in PASMC starving medi-
um for 72 h. Following wash-out with PBS, inserts containing
PMECwere placed above PASMC in DMEM-0.2 %FBS con-
taining 0.5 μCi/mL of [3H]-thymidine for 48 h as shown in
Fig. 1. Radioactivity incorporation was quantified as de-
scribed above. All experiments were performed in triplicate.
Data are expressed as fold increase vs. control (in the absence
of PMECs).
Fig. 1 Diagram of PMECs and PASMCs in co-culture
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PMEC adhesiveness for monocytes
Subconfluent PMECs were starved for 24 h and stimulated
with 10 μg/mL CRP or 10 ng/mL TNFα for 3 h. Human
monocytic U937 cells in suspension were radio-labelled with
1 μCi [3H]-thymidine per 106 cells for 48 h and added (5 × 105
per well) to the endothelial cell monolayer for 3 h at 37 °C.
Non-adherent cells were washed out. Radioactivity incorpo-
rated into monocytes in suspension and attached to the EC
monolayer was quantified as previously described [47]. Data
are expressed as percentage of adhering cells over cells
initially added.
Adhesion molecule expression and quantification
PMEC seeded onto fibronectin-coated chamber slides were
stimulated with 10 μg/mL CRP for 3 h at 37 °C. PMEC were
not permeabilized in order to detect only adhesion molecules
expressed at the cell surface. ICAM-1 and VCAM-1 expres-
sion was detected by immunofluorescence using antibodies
against ICAM-1 and VCAM-1 (dilution 1:50). TNFα
(10 ng/mL) was used as a positive control. For quantification
of immunofluorescence staining, 10 images from non-
overlapping fields on each slide were captured at 40× magni-
fication. Cells were counted by a single observer, unaware of
the identity of each section. PMEC displaying a positive stain-
ing at their surface were considered positive for the specific
staining and results were expressed as the percentage of cells
expressing the cell surface adhesion molecule over total num-
ber of cells.
RNA isolation and reverse transcription
Total RNAwas extracted from lung tissue, PMEC and micro-
vascular PASMC by a single-step method (TRIzol) based on
the guanidium isothiocyanate acid phenol method, followed
by on column-based purification using RNeasy mini kit.
Genomic DNA was removed by enzymatic digestion with
DNase I (Qiagen). RNA integrity and quantity were evaluated
using a chip-based nucleic acid separation system (Prokaryote
Total RNA 6000 Nano assay) on the Agilent 100 Bioanalyzer
(Agilent Technologies). First-strand cDNA was generated
from 1 μg total RNA by reverse transcription using
SuperScript™ III system.
Quantitative real-time polymerase chain reaction
Expression levels of BMPR2, ICAM-1, VCAM-1, ECE-1,
and the housekeeping gene β-actin were determined by quan-
titative real-time polymerase chain reaction (qrt-PCR). First-
strand cDNAwas incubated for 2 min at 50 °C, denatured for
10 min at 95 °C, and subjected to 40 amplification cycles
alternating between annealing/extension at 60 °C for 1 min
followed by denaturation at 95 °C for 15 s using a thermal
cycler (Eco™ Real-Time PCR System, Illumina). Relative
expressionwas calculated using the comparativeΔCtmethod:
2 -(Ct gene of interest-Ct housekeeping gene). Primers used were as
follows: BMPR2, forward 5 ′TGCAGGTTCTCGTG
TCTAGG3′ and reverse 5′GGTCCCAACAGTCTTCGATT
3′; ICAM-1, forward 5′CGCTGAGCTCCTCTGCTACT3′
and reverse 5′TAGGCAACGGGGTCTCTATG3′; VCAM-1,
forward 5′AACCTTGCAGCTTACAGTGA3′ and reverse 5′
TGTGTGAAGGAGTTAATTTGATTGG3′; β-actin, forward
5 ′GGACATCCGCAAAGACCTGT3 ′ and reverse 5 ′
CTCAGGAGGAGCAATGATCTTGAT3′.
Western blotting
Snap-frozen lung tissue samples were homogenized using a tis-
sue homogenizer (Ultra-Turrax T25, Janke&Kunkel) in ice-cold
homogenization buffer containing 50 mM Tris, pH 8.0, 10 mM
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate), 2 mM EDTA, 2 mM EGTA, 1 μg/mL
leupeptin, and 1 μg/mL antipain (Complete Mini Protease
Inhibitor Cocktail, Roche Diagnostics). Homogenates were cen-
trifuged at 4 °C to remove insoluble material and supernatants
were collected. Protein concentrations were determined by the
Bradford method [2]. Protein lysates were solubilized in
Laemmli buffer, and disulphide bridges were reduced in the
presence ofβ-mercaptoethanol for 5 min at 95 °C. Proteins were
further separated on a 10 % acrylamide gel by SDS-PAGE.
Proteins were transferred to polyvinylidenefluoride (PVDF) fil-
ters by electroblotting for 3 h in a transfer buffer containing
25 mM Tris, pH 8.1–8.5, 192 mM glycine, and 20 % methanol.
After blocking in Tris-buffered saline (TBS) containing 0.1 %
Tween-20 (TBS-Tween) containing 5 % non-fat dry milk for 1 h
at room temperature with rocking, the membrane was incubated
with rabbit anti-human BMPRII or anti-β-actin antibodies over-
night at 4 °C in TBS-Tween containing 5 % non-fat dry milk.
The membrane was then washed three times for 10 min in TBS-
Tween and incubated with a secondary antibody conjugated with
horseradish peroxidase, donkey anti-rabbit immunoglobulin
(Ig)G for anti-BMPRII, and anti-mouse IgG for anti-β-actin in
TBS-Tween for 1 h at room temperature. Peroxidase staining
was revealed with a chemiluminescence kit (GE Healthcare),
imaged with the Proxima 2850T imaging system (Isogen Life
Science) and analysed using the software Totallab (Isogen Life
Science).
Endothelin (ET)-1, interleukin (IL)-6, and IL-8
measurement
Confluent PMEC were starved for 24 h. Fresh medium was
added and conditioned medium was collected after 18 h.
ET-1 levels were measured using an ELISA kit following
the manufacturer ’s instructions (QuantiGlo, R&D
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Systems). Briefly, cell supernatants were incubated in mi-
croplates coated with a rat monoclonal antibody against
ET-1, unbound substances were washed away, and a mouse
monoclonal antibody against ET-1 conjugated to horserad-
ish peroxidase was added to each well. Antibody binding
was revealed using an enhanced luminol/peroxide sub-
strate solution. Similarly IL-6 and IL-8 levels were mea-
sured using an ELISA kit following the manufacturer’s
instructions (Quantikine, R&D Systems). Briefly, cell su-
pernatants were incubated in microplates coated with a
mouse monoclonal antibody against IL-6 or IL-8, unbound
substances were washed away, and a rabbit polyclonal an-
tibody against IL-6 or IL-8 conjugated to horseradish per-
oxidase was added to each well. Antibody binding was
revealed using a tetramethylbenzidine/peroxide substrate
solution.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
4.01 (GraphPad Software Inc., La Jolla, California).
Differences between two and three groups were analysed
using Student t test and ANOVA followed by Tukey post
hoc test. Two-way ANOVA test was performed followed
by Bonferonni post hoc test. Associations between vari-
ables were analysed using Pearson’s correlation. A value
of p < 0.05 was considered statistically significant. All p-
values are for two-sided tests. Data are expressed as
mean ± SEM.
Results
Patient characteristics and description of BMPR2
mutations
Patient characteristics at diagnosis and at lung transplanta-
tion are listed in Table 1. We did not observe any difference
in age, gender, body mass index, 6-min walking distance,
circulating CRP levels, mPAP, cardiac output, cardiac
index, PVR, total vascular resistance, whereas right atrial
pressure, and PAWP were significantly increased in
BMPR2 mutation carriers at diagnosis. BMPR2 mutation
carrier 1 has a nonsense mutation in exon 6 [c.631C > T;
p. Arg2111X]; BMPR2 mutation carrier 2 has a missense
mutation in exon 7 [c.901 T > C p. Ser301Pro]; BMPR2
mutation carrier 3 has a missense mutation in exon 3
[c.280 T > G p. Cys94Gly] [20]; BMPR2 mutation carrier
4 has a deletion of exon 10; BMPR2 mutation carrier 5 has
a truncating mutation in exon 6 [c.782_783del, p.
Ile261serfsX4].
Microvascular PMEC and PASMC characterization
PMECs isolated from controls, non-carriers, and BMPR2
mutation carriers demonstrated Ac-LDL uptake (Fig. 2a–
c), expressed CD31 at their surface (Fig. 2d–f) and
contained vWF in Weibel-Palade bodies (Fig. 2g–i). In
addition, FACS analysis showed that PMECs expressed
CD31 at their surface (Fig. 2j–m). PASMCs isolated
from controls, non-carriers, and BMPR2 mutation carriers
Table 1 Patient characteristics at diagnosis and lung transplantation
Diagnosis Lung Transplantation
Non-carriers n = 7 Carriers n = 5 p value (ANOVA,
chi-square)
Non-carriers n = 7 Carriers n = 5 p value (ANOVA,
chi-square)
Age, years 21 ± 12 28 ± 4 0.34 29 ± 10 43 ± 8 0.07
Gender, % male 43 40 0.92 43 40 0.92
BMI, kg.m−2 23 ± 5 23 ± 4 0.93 22 ± 5 20 ± 3 0.43
6MWD, m 396 ± 178 386 ± 111 0.73 343 ± 75 403 ± 115 0.41
CRP, mg.L−1 4.8 ± 4.7 6.3 ± 3.3 0.57 12.1 ± 16.7 6.2 ± 3.6 0.64
RAP, mmHg 5.8 ± 3.1 11 ± 4 0.03 11.5 ± 5.7 10.4 ± 4.8 0.66
mPAP, mmHg 55 ± 11 65 ± 17 0.34 73 ± 27 53 ± 2 0.43
PAWP, mmHg 6 ± 1 13 ± 5 0.009 11 ± 6 NA –
CO, L.min−1 4.6 ± 2.0 4.0 ± 1.5 0.75 4.7 ± 2.1 4.6 ± 2.0 1.00
CI, L min−1.m2 2.6 ± 1.0 2.3 ± 0.8 0.54 2.2 ± 1.1 2.3 ± 1.3 0.93
PVR, dyne.s.cm−5 1193 ± 758 1420 ± 726 0.76 1214 ± 741 NA –
TPR, dyne.s.cm−5 1273 ± 806 1529 ± 842 0.76 1502 ± 756 1213 ± 891 0.61
BMI body mass index, 6MWD six-minute walking distance, CRP C-reactive protein, RAP right atrial pressure,mPAPmean pulmonary arterial pressure,
PAWP pulmonary arterial wedge pressure, CO cardiac output, CI cardiac index, PVR pulmonary vascular resistance, TPR total pulmonary resistance
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displayed α-SMA filaments and expressed desmin and
SMMHC (Fig. 3). Quantitative analysis of the percentage
of positive cells is represented in Table 2; more than
80 % of PMECs from controls, non-carriers, and
BMPR2 mutation carriers had Ac-LDL uptake and
expressed CD31 and vWF at their surface; moreover,
more than 80 % of PASMCs from controls, non-carriers,
and BMPR2 mutation carriers express smooth muscle
differentiation markers including α-SMA, desmin, and
SMMHC (Table 2).
BMPR2 mRNA and protein expression
In our settings, we could not detect any significant difference
in relative BMPR2 mRNA expression in lung tissue between
BMPR2 mutation carriers (2.43 ± 0.80), non-carriers
(3.89 ± 0.88), and controls (3.95 ± 0.11; ANOVA, p = 0.06;
Fig. 4a). Similarly, we could not detect any significant differ-
ence in BMPR2 mRNA expression both in PMEC (carriers,
3.39 ± 1.41, non-carriers, 2.86 ± 1.28, and controls,
5.76 ± 2.24; ANOVA, p = 0.09; Fig. 4d), and in PASMC
Fig. 2 PMEC phenotyping.
PMECs isolated from pulmonary
arteries of controls (a, d, g), non-
carriers (b, e, h), and BMPR2
mutation carriers (c, f, i) were
stained with Dil-Ac-LDL (a–c)
and immuno-labelled with
antibodies raised against CD31
(d–f) and vWF (g–i). Nuclei were
counterstained using DAPI
(blue). CD31 expressed at the
surface of PMECs isolated from
pulmonary arteries of controls (l),
non-carriers (m), and carriers (k)
was quantitatively analysed by
flow cytometry, compared with
unlabelled PMECs (j). PMECs
were characterized at passage 4.
Scale 50 μm
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(carriers, 0.67 ± 0.56, non-carriers, 0.54 ± 0.23, and controls,
1.09 ± 0.49; ANOVA, p = 0.24; Fig. 4c). Moreover, relative
protein expression of BMPRII in the lung tissue was not sta-
tistically different in BMPR2 mutation carriers (4.20 ± 1.94)
and in non-carriers (5.22 ± 0.23) versus controls (7.07 ± 1.76;
p = 0.30; Fig. 4b).
PASMC proliferative properties
Mitogenic activity of PASMC in response to 5 % FBS ap-
peared higher in BMPR2 mutation carriers (4.1 ± 3.2-fold)
compared with non-carriers (2.7 ± 1.5-fold) and controls
(2.0 ± 0.6-fold) (p = 0.14; Fig. 5).
Using a co-culture approach, resting PMEC induced
PASMC mitogenic activity to a greater extent in BMPR2 mu-
tation carriers (4.9 ± 1.0-fold increase) than in non-carriers
(2.8 ± 0.4-fold, p < 0.05) and controls (2.6 ± 0.2-fold,
p < 0.05), (Fig. 6a). In addition, cross-over co-culture exper-
iments showed that PMECs isolated from carriers induced
enhanced mitogenic activity of PASMCs isolated from non-
carriers (1.5 ± 0.17-fold, p < 0.01), while PMECs isolated
from non-carriers did not induce mitogenic activity of
PASMCs isolated from carriers (1.2 ± 0.32-fold, p = 0.32)
(Fig. 6b). These data suggest that PMECs from BMPR2 mu-
tation carriers have an enhanced proliferative effect on
PASMCs, potentially driven by altered BMPRII signalling
and/or downstream effectors; this could be attributed to
Fig. 3 PASMC phenotyping. (a, d, g) PASMCs isolated from pulmonary
arteries of controls, (b, e, h) non-carriers, and (c, f, i) BMPR2 mutation
carriers were immuno-labelled with antibodies raised against α-SMA
(a–c), desmin (d–f), and SMMHC (g–i). Nuclei were counterstained
using DAPI (blue). PASMCs were characterized at passage 3. Scale
50 μm
Table 2 PMEC and PASMC characterization
Controls (%) Non-carriers (%) Carriers (%)
PMECs
Ac-LDL 94.7 ± 5.5 91.3 ± 2.5 93.3 ± 0.6
CD31 82.7 ± 6.0 91.7 ± 2.5 88.0 ± 7.0
CD31 (FACS) 98.4 ± 0.8 97.1 ± 2.1 98.7 ± 1.2
vWF 89.3 ± 2.5 86.3 ± 7.4 85.7 ± 5.6
PASMCs
α-SMA 86.3 ± 3.1 90.0 ± 5.0 87.7 ± 2.1
Desmin 86.0 ± 5.6 80.6 ± 13.3 88.7 ± 3.1
SMMHC 83.0 ± 6.6 82.0 ± 13.0 87.7 ± 4.0
Results are expressed as percentage of alive cells
Ac-LDL acetylated-LDL, vWF von Willebrand factor, α-SMA α-smooth
muscle actin, SMMHC smooth muscle myosin heavy chain, PMEC pul-
monary microvascular endothelial cells, PASMC pulmonary arterial
smooth muscle cells
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enhanced ET-1 secretion, as ET-1 secretion by PMEC is sig-
nificantly higher (ANOVA, p = 0.01) in BMPR2 mutation
carriers (162 ± 34 pg/mL) compared with non-carriers
(66 ± 16 pg/mL) and controls (33 ± 9 pg/mL) (Fig. 6c).
Interestingly, PMEC-induced PASMC mitogenic activity
was correlated with ET-1 levels secreted by PMECs
(r = 0.76, p = 0.04). However, we did not observe any signif-
icant difference in the levels of mRNA coding for endothelin
converting enzyme-1 (ECE-1), which hydrolyses big
endothelin into ET-1, between PMEC from BMPR2 mutation
carriers (22.9 ± 14.1), non-carriers (3.9 ± 1.1) and controls
(7.1 ± 3.6). Moreover, we did not find any correlation between
individual values of secreted ET-1 and ECE-1 mRNA
expression.
PMEC adhesiveness for monocytes and proliferative
properties
PMEC mitogenic activity in response to 5 % FBS was
similar in controls, non-carriers, and BMPR2 mutation
carriers (1.5 ± 0.2-; 2.0 ± 0.2-; 1.8 ± 0.3-fold increase,
respectively).
Basal adhesiveness of human monocytic cells (U937) to
resting PMECs was significantly higher in non-carriers
(10 ± 2 %, p < 0.05) and BMPR2 mutation carriers
(10 ± 2 %, p < 0.05), compared with controls (2 ± 0.3 %)
(Fig. 7a). Interestingly, ICAM-1 mRNA expression was sig-
nificantly higher in resting PMECs from carriers compared
Fig. 4 BMPR2 expression. BMPR2mRNA expression (a) in lung tissue
(ANOVA, p = 0.06), (d) PMECs (ANOVA, p = 0.09) and (c) PASMCs
(ANOVA, p = 0.33). (b) Representative image of BMPRII and β-actin
protein expression by Western blotting and quantitative BMPRII protein
expression in lung tissue (ANOVA, p = 0.30)
Fig. 5 PASMC proliferative capacities. Mitogenic activity of PASMCs
isolated from controls (n = 4), non-carriers (n = 7), and BMPR2mutation
carriers (n = 5) in response to 5 % FBS (ANOVA, p = 0.31). Independent
experiments were performed in triplicate between passages 3 and 5. Data
are shown as fold increase vs. 0.2 % FBS
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with controls (p < 0.05) (Table 3). In addition, ICAM-1 ex-
pression appeared increased at the surface of PMECs from
carriers and to a lesser extent from non-carriers (ANOVA,
p = 0.09; Fig. 7h). VCAM-1 expression was significantly
increased at the surface of carrier PMECs compared with
controls and non-carriers (ANOVA, p < 0.05) (Fig. 7i,
Table 4), whereas VCAM-1 mRNA expression was similar
in controls, non-carriers and BMPR2 mutation carriers
(Table 3).
Effects of an inflammatory trigger on PASMCs
and PMECs
CRP-induced PASMC mitogenic activity was similar in
BMPR2 mutation carriers (1.9 ± 0.7-fold), non-carriers
(1.5 ± 0.7-fold) and controls (1.1 ± 0.6-fold) (ANOVA,
p = 0.23).
Adhesiveness of U937 cells to TNFα-activated PMECwas
significantly higher in BMPR2 mutation carriers (50 ± 6 %,
p < 0.05) compared with controls (26 ± 7 %) (Fig. 8a). In
response to CRP, adhesiveness capacity was significantly
higher in PAH patients (carriers, 15 ± 0.6 %, p < 0.001 and
non-carriers, 9 ± 1.6 %, p < 0.05) than in controls (2 ± 0.3 %)
(Fig. 8b).
ICAM-1 mRNA expression was significantly elevated
in PMECs from BMPR2 mutation carriers, compared to
non-car r ie rs and cont ro ls , s t imula ted by CRP
(p = 0.011); however, CRP did not induce any increase
in ICAM-1 mRNA expression in PMECs from BMPR2
mutation carriers, non-carriers, or controls (Table 3).
CRP had no effect on VCAM-1 mRNA expression in
PMECs from BMPR2 mutation carriers, non-carriers, or
controls (Table 3). CRP had limited effect on ICAM-1
protein expression at the surface of PMECs from non-
carriers and BMPR2 mutation carriers, whereas it in-
duced ICAM-1 expression in PMECs from controls
(Table 4, Fig. 9).
TNFα significantly increased ICAM-1 mRNA expres-
sion in PMECs from controls, BMPR2 mutation carriers,
and non-carriers (p < 0.0001) and to a greater extent in
PMECs from BMPR2 mutation carriers and non-carriers
(ANOVA, p = 0.06; Table 3). TNFα also significantly
increased VCAM-1 mRNA expression in PMECs from
controls, BMPR2 mutation carriers and non-carriers
(p < 0.0001); surprisingly, TNFα-induced VCAM-1
mRNA expression was lower in PMECs from carriers
compared with PMECs from controls (p < 0.05;
Table 3). TNFα increased ICAM-1 expression at the sur-
face of PMECs from controls, non-carriers, and BMPR2
mutation carriers, with an enhanced effect on PMECs
from BMPR2 mutation carriers (Table 4, Fig. 9). In addi-
tion, TNFα induced increased VCAM-1 expression in
PMECs from non-carriers and BMPR2 mutation carriers,
with an enhanced effect in PMECs from BMPR2 mutation
carriers (Table 4, Fig. 9).
TNFα and CRP significantly induced IL-6 production by
PMECs from BMPR2 mutation carriers but had no effects on
IL-8 production (Fig. 10).
Fig. 6 Co-culture of PMECs and PASMCs. (a) Mitogenic activity of
PASMCs in co-culture with resting PMEC (ANOVA, p = 0.02;
**p < 0.05, *p < 0.05). (b) Mitogenic activity of PASMCs from a non-
carriers (n = 3) and BMPR2 mutation carriers (n = 3) in cross co-culture
with resting PMEC from non-carriers (n = 3) and BMPR2 mutation
carriers (n = 3) (ANOVA, p = 0.04; *p < 0.01 vs. 0.2 % FBS). (c) ET-1
secretion by resting PMECs (ANOVA, p = 0.01; *p < 0.05). Independent
experiments were performed in triplicate between passages 3 and 5.
Mitogenic activity data are shown as fold increase vs. 0.2 % FBS
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Discussion
In the present study, we showed that compared with PMECs
from non-carriers, PMECs from BMPR2 mutation carriers
have increased adhesiveness to monocytes, enhanced by
CRP and TNFα. Moreover, PMECs from BMPR2 mutation
carriers enhanced PASMC mitogenic activity in co-culture
and secreted higher levels of ET-1, a potent pulmonary vaso-
constrictor and one of the main therapeutic target in PAH.
These observations suggest a dysfunction of PMECs in
BMPR2mutation carriers, potentially enhanced by inflamma-
tory mediators such as CRP or TNFα.
Effects of BMPR2 mutations on pulmonary vascular
function
In our settings, BMPRII protein expression was not different
between BMPR2 mutation carriers and non-carriers. The cur-
rent 300 listed BMPR2 mutations include missense and non-
sense mutations; whereas nonsense mutations result mostly in
Fig. 7 PMEC adhesiveness to
monocytes. (a) Adhesiveness of
PMECs isolated from controls
(n = 3), non-carriers (n = 5) and
BMPR2 mutation carriers (n = 3)
to the monocytic cell line U937 at
baseline (ANOVA, p = 0.04;
*p < 0.05). Data are shown as
percentage of adhering U937
cells. Surface expression of
ICAM-1 (b-d) and VCAM-1 (e-
g) in PMECs from controls (b, e),
non-carriers (c, f) and carriers (d,
g). (h) Percentage of PMECs
expressing ICAM-1 (ANOVA,
p = 0.09). (i) Percentage of
PMECs expressing VCAM-1
(ANOVA, p = 0.03; *p < 0.05).
Experiments were performed in
triplicate for PMECs from each
patient between passages 4 and 7
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truncated protein, missense mutations may have no conse-
quence on the protein size but can result in a loss of protein
function. Serum-induced PASMC mitogenic activity was not
higher in BMPR2 mutation carriers compared with controls
and non-carriers, in agreement with previous studies [5, 26],
although in contrast with the findings by Dewachter et al. [6].
However, the high variability in the in vitro mitogenic re-
sponse of PASMC could be attributed to the type of BMPR2
mutation since the two highest mitogenic responses were
found in PASMC isolated from carriers of entire exon dele-
tion, i.e., exons 2 and 3, and exon 10, whereas the two lowest
were observed in carriers of missense mutations and the inter-
mediate one in carrier of a nonsense mutation. This suggests
that PASMC proliferative capacities can be driven by the type
of BMPR2 mutation.
In addition, when co-cultured, resting PMECs increased
PASMC mitogenic activity in controls, non-carriers and, to a
greater extent, in PASMCs isolated from BMPR2 mutation
carriers. Intriguingly, PMECs from BMPR2 mutation carriers
also increased the mitogenic activity of PASMCs from non-
carriers. These effects could be attributed to increased secre-
tion of ET-1, a potent PASMC mitogen, by PMECs from
BMPR2 mutation carriers (Fig. 5b), in agreement with pre-
vious studies showing increased ET-1 secretion in PMECs
from BMPR2 mutation carriers and BMPR2 knocked-down
PMECs [8, 44]. However, the increase in ET-1 secretion by
PMECs from BMPR2 mutation carriers does not appear to be
linked to any change in ECE-1 expression. Interestingly, we
found a correlation between ET-1 secretion by PMECs and
PMEC-induced PASMC mitogenic activity, suggesting that
ET-1 could mediate enhanced effects of PMECs of BMPR2
mutation carriers on PASMC.
Moreover, we showed a higher adhesiveness of resting
PMECs from non-carriers and BMPR2 mutation carriers for
monocytes which could be attributed to increased ICAM-1
mRNA expression and ICAM-1 and VCAM-1 protein expres-
sion at cell surface. This is in agreement with a previous ob-
servation of enhanced ICAM-1 and VCAM-1 expression in
BMPR2-knockdown human umbilical vein endothelial cells
[16] and increased leukocyte recruitment by BMPR2-
Table 3 Adhesion molecules mRNA expression in PMECs
Resting Controls Non-carriers Carriers ANOVA, p value
ICAM-1 1.5 × 10−3 ± 0.3 × 10−3 5.6 × 10−3 ± 2.9 × 10−3 12.3 × 10−3 ± 2.8 × 10–3# 0.018
VCAM-1 6.3 × 10−4 ± 1.2 × 10−4 2.2 × 10−4 ± 1.5 × 10−4 8.5 × 10−4 ± 5.2 × 10−4 0.39
+ CRP Controls Non-carriers Carriers ANOVA, p value
ICAM-1 1.5 × 10−3 ± 0.3 × 10−3 4.2 × 10−3 ± 2.3 × 10−3 8.0 × 10−3 ± 2.8 × 10−3* 0.011
VCAM-1 5.0 × 10−4 ± 1.2 × 10−4 2.0 × 10−4 ± 1.1 × 10−4 4.6 × 10−4 ± 2.3 × 10−4 0.40
+ TNFα Controls Non-carriers Carriers ANOVA, p value
ICAM-1 0.11 ± 0.01§ 0.25 ± 0.06§ 0.24 ± 0.05§ 0.06
VCAM-1 0.17 ± 0.03§ 0.09 ± 0.03# 0.04 ± 0.02*$ 0.02
ANOVA, p value
ICAM-1
<0.0001 <0.0001 <0.0001
ANOVA, p value
VCAM-1
<0.0001 0.002 0.005
Experiments were performed in triplicate for PMECs from each patient between passages 4 and 7
CRP C-reactive protein, ICAM-1 intercellular adhesion molecule-1, TNFα tumour necrosis factor α, VCAM-1 vascular cell adhesion molecule-1
*p < 0.05 vs. controls; § p < 0.001 vs. resting; # p < 0.01 vs. resting; $ p < 0.05 vs. resting
Table 4 Adhesion molecule expression at PMEC surface
Resting Controls Non-carriers Carriers ANOVA, p value
ICAM-1 16 ± 4 32 ± 4 39 ± 8 0.09
VCAM-1 19 ± 2 17 ± 4 34 ± 2*# 0.03
+ CRP Controls Non-carriers Carriers ANOVA, p value
ICAM-1 32 ± 5§ 35 ± 9 43 ± 5 0.57
VCAM-1 26 ± 4 27 ± 6 35 ± 7 0.53
+ TNFα Controls Non-carriers Carriers ANOVA, p value
ICAM-1 43 ± 3§ 47 ± 7 62 ± 4 0.07
VCAM-1 25 ± 3 38 ± 5§ 49 ± 5* 0.04
ANOVA, p value
ICAM-1
0.008 0.22 0.07
ANOVA, p value
VCAM-1
0.28 0.02 0.18
Experiments were performed in triplicate for PMECs from each patient
between passages 5 and 7
CRP C-reactive protein, ICAM-1 intercellular adhesion molecule-1,
TNFα tumour necrosis factor α, VCAM-1 vascular cell adhesion mole-
cule -1
*p < 0.05 vs. controls; # p < 0.05 vs. non-carriers; § p < 0.05 vs. resting.
Results are expressed as percentage of alive cells
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Fig. 8 Effects of inflammatory mediators on PMEC adhesiveness for
monocytes. Adhesiveness capacity of PMECs isolated from controls
(n = 3), non-carriers (n = 5), and BMPR2 mutation carriers (n = 3) to
the monocytic cell line U937 in response to (a) TNFα (10 ng/ml);
ANOVA, p = 0.04; *p < 0.05 and (b) CRP (10 μg/ml); ANOVA,
p = 0.001, *p < 0.05, and **p < 0.001. Data are shown as percentage
of adhering U937 cells. Experiments were performed in triplicate for
PMECs from each patient between passages 4 and 7
Fig. 9 Effects of inflammatory
mediators on adhesion molecule
expression at PMEC surface.
Expression at surface of PMECs
from controls (a, d, g, j), non-
carriers (b, e, h, k), and BMPR2
mutation carriers (c, f, i, l) of
ICAM-1 (a-f) and VCAM-1 (g-l),
after a 3-h stimulation with CRP
(a-c, g-i) or TNFα (d-f, j-l).
Experiments were performedwith
PMECs from each patient
between passages 5 and 7. Scale
100 μm
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knockdown human PMEC [3]. Interestingly, BMPR2 genetic
ablation in mouse pulmonary endothelium resulted in peri-
vascular leukocyte infiltration, in situ thrombosis and predispo-
sition to PAH [12]. Finally, various functional changes were
observed in the pulmonary endothelium in association with
BMPRII dysfunction, including apoptosis [46], DNA damage
[18] and pulmonary endothelial barrier dysfunction [29].
Effects on inflammatory triggers on pulmonary
microvascular endothelial cells
Considering the low penetrance of a BMPR2 mutation, a
Bsecond hit^ may be required for the development of PAH,
in addition to a BMPR2 mutation [23, 27]. Increased inflam-
matory mediators, such as circulating CRP and interleukins,
have been observed in PAH and were shown to predict sur-
vival [31, 40]. Consequently, we hypothesized that inflamma-
tory mediators could contribute to endothelial dysfunction in
PAH. We found that CRP and TNFα increased adhesiveness
of U937 monocytic cells to PMEC from BMPR2 mutation
carriers, suggesting that BMPRII protein dysfunction could
enhance the response of endothelium to inflammatory media-
tors. In BMPR2 mutation carriers, CRP-mediated adhesive-
ness of PMECs for monocytes could be attributed to a
moderate expression of ICAM-1 at the surface of PMECs,
whereas TNFα-mediated adhesiveness of PMECs for mono-
cytes could be due to enhanced VCAM-1 mRNA expression
and protein expression at the surface of PMECs. In non-car-
riers, CRP-mediated adhesiveness could be due to VCAM-1
expression at the surface of PMECs and TNFα-mediated ad-
hesiveness to enhanced VCAM-1 mRNA expression and to
expression of both ICAM-1 and VCAM-1 at the surface of
PMECs. Moreover, we observed that both TNFα and CRP
induced the production of IL-6 by PMECs from BMPR2 mu-
tation carriers, in agreement with previous studies demonstrat-
ing increased levels of circulating IL-6, shown to predict out-
come and impaired survival in PAH [11, 14, 40]. Our findings
are also in agreement with recent observations showing that (i)
mice carrying a mutant BMPR2 allele lacking exons 4 and 5
harboured mild pulmonary hypertension and impaired
pulmonary vascular remodelling under hypoxia [1], (ii) acute
exposure to LPS of BMPR2+/− mice resulted in enhanced
production of inflammatory mediators such as IL-6 and
KC/IL-8 [39], (iii) pulmonary artery SMC from BMPR2+/−
mice and patients with BMPR2 mutations produced induced
secretion of IL-6 and KC/IL-8 [39], and (iv) rats expressing a
BMPR2 mutant harbour remodelling of distal pulmonary
arteries [34].
Fig. 10 Effects of inflammatory mediators on IL-6 and IL-8 secretion by
PMECs. Secretion of IL-6 (a, b) and IL-8 (c, d) in the presence of TNFα
(a, c) or CRP (b, d) by PMECs isolated from controls (n = 3), non-carriers
(n = 3) and BMPR2 mutation carriers (n = 3). Experiments were
performed with PMECs between passages 5 and 7. (a) ANOVA,
p = 0.03; *p < 0.05. (b) ANOVA, p = 0.05; *p < 0.05
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Limitations
As pulmonary vascular cells were isolated at the time of lung
transplantation, the results from the present study may reflect
advanced stages of the disease rather than early pathogenesis.
In addition, the low number of patients included could be seen
as a constraint; one should highlight that i) IPAH and HPAH
are rare diseases and ii) only a very low percentage of patients
can benefit from lung transplantation, thus limiting access to
human tissue. Regarding the potential crosstalk between
PMECs and PASMCs in a context of mutated BMPR2 gene,
it would be relevant to further investigate the effects of ET-1
receptor antagonists.
Conclusion
We report that inflammatory mediators may contribute to pul-
monary microvascular endothelial cell dysfunction in BMPR2
mutation carriers with PAH. Since BMPR2 mutation carriers
have increased pulmonary vascular cell mitogenic activity and
in vitro CRP-induced adhesiveness of PMECs for monocytes,
we suggest that BMPR2mutations may increase susceptibility
of the pulmonary endothelium to adverse effects of inflamma-
tory mediators.
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